Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai Chest Hospital
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC based on the 8th edition of the AJCC staging system.
Previously received first-line treatment with Tislelizumab for advanced NSCLC.
Medical records of disease progression after first-line treatment.
You may not be if
Patients with incomplete key baseline and treatment information，including clinical stage, pathological type, treatment regimen, tumor assessment record after treatment ect.
Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown.
Clareo Health | Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
